We take AI drug discovery platforms into pharma.
An operator-led business development partner for AI-native discovery companies, from the first introduction to a signed term sheet.
Strong science rarely moves a pharma deal on its own.
Pharma evaluates AI platforms through long internal processes that an outside company cannot see into, and the people who decide are hard to reach. Most platforms share the same profile: strong science, a validated engine, a small team, and little commercial capacity to reach pharma. Building that capacity in-house takes a raise and a hiring cycle, and the partnering window often closes first.
We never claim your IP, your molecules, or your designs.
CADENCE, our partnering method.
Four stages from a mapped account universe to a signed term sheet. We walk partners through how it applies to their programme in conversation.
Map
The pharma account universe for your platform, and the R&D functions that decide.
Frame
A commercial thesis in pharma’s own vocabulary, anchored to comparable transactions.
Reach
Introductions to the decision-makers who are hard to reach from outside.
Close
The deal carried through every stage gate to a signed term sheet.
One pharma problem, several platforms, one offer.
Pharma R&D heads look for solutions no single platform can offer. We assemble complementary capabilities into one offer matched to a specific pipeline problem, so each company reaches a deal it could not close alone.
How pharma buys it
- Target validationCompany A
- Antibody designCompany B
- Optimisation chemistryCompany C
- In-vivo validationCompany D
The engagement model
A monthly retainer covers the method from account mapping to active partnering conversations. Commission applies only to signed deals we helped create, and the structure is set per company at signing.
Operators pharma recognises
Our founding operators built senior commercial careers across global pharma, including general management and global brand leadership. The counterpart across the table has usually walked the same path.
For biotech and therapeutics
The same partnering work, for biotech companies.
Biotech and therapeutics companies, AI-enabled or not, get the same business development work: pharma partnering from the first introduction to a signed term sheet.
The pharma account universe
The partners for your asset or platform, and the functions inside them that decide.
A thesis in pharma’s vocabulary
Your commercial case, anchored to comparable transactions.
Introductions
The decision-makers who are hard to reach from outside.
Through to term sheet
The deal carried through every stage gate to a signed term sheet.